Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Trevor J Kilpatrick

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Plos One|November 5, 2010
A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosisJudith Field, Sharon R Browning, Laura J Johnson, et al.
Human Molecular Genetics|July 19, 2015
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosisBen J Gu, Judith Field, Sébastien Dutertre, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Annals of Neurology|October 10, 2025
Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis OnsetSteve Simpson-Yap, Ellen Morwitch, Samuel A Tanner, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Brain : a Journal of Neurology|November 30, 2022
Not all roads lead to the immune system: the genetic basis of multiple sclerosis severityVilija G Jokubaitis, Maria Pia Campagna, Omar Ibrahim, et al.
Nature Communications|October 22, 2024
In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditionsGeorgia K Atkin-Smith, Jascinta P Santavanond, Amanda Light, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Plos One|November 5, 2010
A polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosisJudith Field, Sharon R Browning, Laura J Johnson, et al.
Human Molecular Genetics|July 19, 2015
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosisBen J Gu, Judith Field, Sébastien Dutertre, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 5, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|July 3, 2014
Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of NeurologistsSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Annals of Neurology|October 10, 2025
Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis OnsetSteve Simpson-Yap, Ellen Morwitch, Samuel A Tanner, et al.
The Medical Journal of Australia|July 31, 2015
A new era in the treatment of multiple sclerosisSimon A Broadley, Michael H Barnett, Mike Boggild, et al.
Brain : a Journal of Neurology|November 30, 2022
Not all roads lead to the immune system: the genetic basis of multiple sclerosis severityVilija G Jokubaitis, Maria Pia Campagna, Omar Ibrahim, et al.
Nature Communications|October 22, 2024
In situ visualization of endothelial cell-derived extracellular vesicle formation in steady state and malignant conditionsGeorgia K Atkin-Smith, Jascinta P Santavanond, Amanda Light, et al.
Brain : a Journal of Neurology|October 22, 2013
Sex as a determinant of relapse incidence and progressive course of multiple sclerosisTomas Kalincik, Vino Vivek, Vilija Jokubaitis, et al.
Pageof 12